Cyclobutyl Dihydroquinoline Sulfonamides for Nav1.7 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sodium channel inhibitors, such as lidocaine and carbamazepine, lack selectivity for Nav1.7, leading to undesirable side effects due to their non-selective blocking of other sodium channel subtypes, particularly Nav1.5, and there is a need for selective inhibitors to treat pain without causing heart-related issues.
Innovation Solution
Development of cyclobutyl dihydroquinoline sulfonamide compounds that selectively inhibit Nav1.7 over Nav1.5, providing a therapeutic approach for pain management with reduced risk of cardiac complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective sodium channel inhibitors (lidocaine, carbamazepine) are used to block pain pathways, then pain relief is achieved, but cardiac safety deteriorates due to non-selective blocking of Nav1.5
Solution Approach 1:
The invention segments the sodium channel blocking action by designing compounds that selectively target specific Nav subtypes (particularly Nav1.7 and Nav1.8) while sparing cardiac Nav1.5 channels. This is achieved through specific molecular structures (dihydroquinoline, tetrahydroquinoline, or indoline cores with particular substituent patterns) that confer subtype selectivity, thereby providing pain relief without cardiac toxicity.
Solution Approach 2:
The invention applies local quality by creating compounds with specific structural features (such as cyclobutyl groups, particular substituent configurations at positions R1-R6) that enable selective interaction with pain pathway sodium channels. The molecular structure is optimized to have high affinity for Nav1.7/Nav1.8 while maintaining low affinity for Nav1.5, achieving localized therapeutic action in pain pathways without affecting cardiac function.
2Object-affected harmful factors
If selective Nav1.7 inhibitors are developed to improve cardiac safety, then cardiac side effects are reduced, but the complexity of achieving selectivity increases
Solution Approach 1:
The invention utilizes parameter changes by systematically varying molecular parameters (substituent types, positions, and configurations on the dihydroquinoline/indoline core) to optimize selectivity between Nav subtypes. By adjusting these chemical parameters, the compounds achieve high Nav1.7/Nav1.8 selectivity while maintaining manageable structural complexity and drug-like properties.
Data Source
AI summary
The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.